TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34352149
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Tenofovir Alafenamide (TAF)
Study: 35797913
Drug: Active iTBS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active iTBS treatment
Study: 35797913
Drug: Sham iTBS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham iTBS treatment
Study: 33377972
Drug: Capivasertib, 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib, 480 mg orally twice daily for 4 days on and 3 days off weekly in 28-day cycles; 400 mg if continuing hormone therapy for metastatic breast cancer.
Study: 34588374
Drug: Royal jelly
Normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Royal jelly 690 mg daily for 4 weeks
Study: 32707226
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids (administered post-reaction)
Study: 35986418
Drug: Injectable buprenorphine
Normalized name: buprenorphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable buprenorphine (BUP-XR) with adjunctive psychosocial interventions (PSI)
Study: 35986418
Drug: Sublingual tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet buprenorphine (BUP-SL)
Study: 35986418
Drug: Sublingual tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablet buprenorphine (BUP-SL) with PSI
Study: 35986418
Drug: Oral liquid
Normalized name: ACAI ORAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid methadone (MET) with PSI
Study: 33605465
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive treatment (Control)
Study: 33496536
Drug: Intraoperative freehand
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative freehand bilateral ESPB with a 20-mL mixture solution of 0.25% bupivacaine and 1.0% lidocaine
Study: 33496536
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline injection (Control)
Study: 32687091
Drug: Intralipid (IL)
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (IL) 20% infusion at 2 ml/kg, 30 min prior to revascularization
Study: 32687091
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received normal saline infusion
Study: 83151875
Drug: Hepatic-Aid diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic-Aid diet (20-g Casein/30-g Hepatic-Aid per day)
Study: 83151875
Drug: Casein diet
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein diet (50-g Casein per day)
Study: 33548749
Drug: Deep tissue
Normalized name: Deep Tissue Percussion Therapeutic Massager
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep tissue massage (DTM) applied by midwife, twice at the 10th and 22nd hour after cesarean.
Study: 34959975
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg Folic Acid
Study: 34959975
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg Folic Acid
Study: 32601955
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic capsules (Bacillus coagulans Unique IS2, Lactobacillus rhamnosus UBLR58, Bifidobacterium lactis UBBLa70, Lactobacillus plantarum UBLP40 each of 2 billion CFU; Bifidobacterium breve UBBr01, Bifidobacterium infantis UBBI01 each of 1 billion CFU) with glutamine (250 mg) taken twice a day for 28 days
Study: 32601955
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken twice a day for 28 days
Study: 34348666
Drug: LTV-h.PEEP ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTV-h.PEEP ventilation (TV of 6 ml/IBW and PEEP of 10 cm H2O)
Study: 34348666
Drug: HTV-l.PEEP ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTV-l.PEEP ventilation (TV of 10 ml/IBW and PEEP of 4 cm H2O)
Study: 32350847
Drug: Nanocurcumin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin (180 mg/day)
Study: 34957008
Drug: Camrelizumab combination
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab combination therapy
Study: 34641706
Drug: PZL (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZL (50 μg)
Study: 34641706
Drug: LT3 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT3 (50 μg)
Study: 34076067
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of CBD powder
Study: 34076067
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of CBD dissolved in corn oil
Study: 32740218
Drug: Rivaroxaban with
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban with or without vitamin K2 or vitamin K antagonists
Study: 32740218
Drug: Regular-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regular-dose apixaban (5 mg twice daily)
Study: 35914222
Drug: Reduced-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reduced-dose apixaban (2.5 mg twice daily)
Study: 33590823
Drug: Lemborexant (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (5 mg and 10 mg)
Study: 35439033
Drug: Chinese Herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Herbal Medicine (SXC) - 3 capsules (0.5 g/capsule) taken 3 times a day for 8 weeks
Study: 33125454
Drug: CERC‐501 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC‐501 (10 mg/d for 6 days)
Study: 33125454
Drug: CERC‐501 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC‐501 (20 mg/d for 6 days)
Study: 33125454
Drug: CERC‐501 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC‐501 (10 mg/d for 3 days after placebo for 3 days)
Study: 33125454
Drug: CERC‐501 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC‐501 (20 mg/d for 3 days after placebo for 3 days)
Study: 35420362
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg daily
Study: 34622768
Drug: Menopur liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopur liquid (450 IU, 600 IU/0.96 mL)
Study: 34622768
Drug: Menopur powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopur powder (450 IU, by 2 subcutaneous injections of 225 IU in 1 mL)
Study: 35683351
Drug: Low-dose hzVSF-v13
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hzVSF-v13
Study: 35683351
Drug: High-dose hzVSF-v13
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hzVSF-v13
Study: 32907828
Drug: Dual-hormone (DH)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual-hormone (DH) closed-loop control
Study: 32907828
Drug: Insulin-only single-hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-only single-hormone (SH) closed-loop control
Study: 32800913
Drug: K levels
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K levels ≥4.5 mEq/L within 36-56 hours prior to AKI diagnosis
Study: 34931749
Drug: Berberine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (600 mg/d)
Study: 33206126
Drug: Tailored self-care
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored self-care intervention (home visit within 7 days of discharge and twice-monthly telephone coaching for 3 months)
Study: 33044213
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light treatment via ear canals
Study: 33270989
Drug: Preoperative C-reactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative C-reactive protein (pre-CRP) ≥3.1 mg/L (high-pre-CRP)
Study: 33270989
Drug: Postoperative maximum
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Postoperative maximum C-reactive protein (post-CRPmax) ≥77.1 mg/L (high-post-CRPmax)
Study: 33270989
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (ACT)
Study: 33270989
Drug: Pre-CRP <3.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-CRP <3.1 mg/L
Study: 35811226
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrates (POC) intake in Fpo and Spo groups
Study: 34780798
Drug: 180 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg/mL rhNGF eye drops, 3 times daily for 8 weeks
Study: 34780798
Drug: 180 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 μg/mL rhNGF eye drops
Study: 33930541
Drug: Seropositivity in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seropositivity in administration staff compared to doctors
Study: 36462032
Drug: High-dose remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose remimazolam (Group H, 0.08 mg/kg)
Study: 36462032
Drug: Medium-dose remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medium-dose remimazolam (Group M, 0.06 mg/kg)
Study: 36462032
Drug: Low-dose remimazolam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remimazolam (Group L, 0.04 mg/kg)
Study: 36462032
Drug: Medium-dose remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medium-dose remimazolam (Group M)
Study: 34415830
Drug: mnemoPQQ® (PQQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: mnemoPQQ® (PQQ disodium salt: 21.5 mg/day)
Study: 34349371
Drug: Laryngeal Mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngeal Mask Airway (LMA) (Group L)
Study: 34351562
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with nano or micro zinc oxide (49, 74, 99, and 124 mg ZnO/kg diet)
Study: 34351562
Drug: Control non-supplemented
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control non-supplemented diet (24 mg/kg)
Study: 32847626
Drug: Prostacyclin (Iloprost)
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours
Study: 33077817
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention (high-intensity interval aerobic fitness and strength training with nutritional supplement)
Study: 34063673
Drug: Percutaneous neuromodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous neuromodulation (PNM) treatment
Study: 32791721
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (3 ml supernatant of maternal vaginal bacteria)
Study: 32791721
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 ml sterile water)
Study: 32791721
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (3 ml supernatant)
Study: 32918971
Drug: Single 19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 19 Gy HDR implant to the whole prostate (Trial1)
Study: 32184185
Drug: Minesapride 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minesapride 12 mg
Study: 36498963
Drug: Methylone 50
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylone 50 mg
Study: 36498963
Drug: Methylone 100
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylone 100 mg
Study: 36498963
Drug: Methylone 150
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylone 150 mg
Study: 36498963
Drug: Methylone 200
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylone 200 mg
Study: 33166056
Drug: CYP2D6 poor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 poor and intermediate metabolizers after the eighth week of treatment
Study: 39094677
Drug: Methylprednisolone 250
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 250 mg
Study: 33982068
Drug: 5 μg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg of ramosetron (Irribow®) daily for 4 weeks
Study: 33982068
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for 4 weeks
Study: 33289844
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 supplementation (2800 IU/d)
Study: 33289844
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose vitamin D3 supplementation (400 IU/d)
Study: 34315522
Drug: Modified resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified resistant starch (40 g/day)
Study: 32091560
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative therapy (OMTh), 4 sessions over 2 months
Study: 32079916
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (2 × 5 g·d)
Study: 32079916
Drug: Alanine supplementation
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alanine supplementation (2 × 5 g·d)
Study: 33744812
Drug: abiraterone/prednisone combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: abiraterone/prednisone combination
Study: 33744812
Drug: enzalutamide combination
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: enzalutamide combination
Study: 33744812
Drug: radium-223 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: radium-223 monotherapy
Study: 32442298
Drug: Fixed-dose enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose enoxaparin (40 mg daily)
Study: 32442298
Drug: Weight-adjusted enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted enoxaparin (1 mg/kg daily)
Study: 33618657
Drug: Last kilometre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Last kilometre medicine delivery service
Study: 33618657
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application for ordering medicines
Study: 33618657
Drug: Home delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home delivery of medicines
Study: 32797125
Drug: Ubiquinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (200 mg day‐1)
Study: 36440058
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera capsules
Study: 32105267
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg once a day at night for 3 months)
Study: 32323103
Drug: AE37 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AE37 vaccine (VG)
Study: 32323103
Drug: GP2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2 vaccine (VG)
Study: 35057577
Drug: Calanus oil
Normalized name: CALANUS OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calanus oil (2 g CO/day)
Study: 35057577
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g paraffin oil/day)
Study: 33278899
Drug: Micronutrient Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient Powder Supplementation (MNP) alongside National Micronutrient Supplement (NMS) - 3 sachets/week for 12 months
Study: 33583158
Drug: Artemisia supplementation
Normalized name: Artemisia vulgaris top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisia supplementation (250 mg/day for six weeks)
Study: 33583158
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg/day for six weeks)
Study: 32358413
Drug: Romosozumab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romosozumab (various doses)
Study: 34969035
Drug: Hedan tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hedan tablets at 4.38 g/day tid
Study: 33461965
Drug: green-MED diet
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: green-MED diet (100 g/day Mankai, 3-4 cups/day green tea, 28 g/day walnuts)
Study: 33461965
Drug: MED diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MED diet (28 g/day walnuts)
Study: 35767123
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) treatment
Study: 32116098
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin treatment
Study: 34531823
Drug: Cannabis treatment
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis treatment for 8 weeks
Study: 32028411
Drug: OPEA+SPOA (preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPEA+SPOA (preemptive oxycodone and postoperative sufentanil)
Study: 33624330
Drug: Anodic tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodic tDCS (A-tDCS) 2 mA for 20 min concurrent with speech language therapy (SLT)
Study: 33624330
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS (S-tDCS) current started at 2 mA but decreased to 0 mA after 30 sec, concurrent with speech language therapy (SLT)
Study: 32865434
Drug: Intra-operative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative wound irrigation with ceftriaxone in normal saline solution
Study: 33524876
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma transfusion and standard therapy (n = 9)
Study: 33524876
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (n = 9)
Study: 35855382
Drug: Virtual painting
Normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virtual painting therapy directed by WhatsApp (six 2-hour group sessions once a week for six weeks)
Study: 32973199
Drug: 2 mg/ml
Normalized name: urea 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/ml phenazine application
Study: 32973199
Drug: 0.048 mg/ml
Normalized name: ipecac 0.048 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.048 mg/ml hexaconazole application
Study: 32973199
Drug: 1 mg/ml
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/ml phenazine application
Study: 32973199
Drug: G. boninense
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. boninense inoculated seedlings
Study: 32470574
Drug: New generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generic S-1 (50 mg)
Study: 32470574
Drug: Original brand-name
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original brand-name S-1 (50 mg)
Study: 34105089
Drug: Prototype mini
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype mini lozenge (2 or 4 mg dose)
Study: 34105089
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available mini lozenge
Study: 34105089
Drug: Prototype mini
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype mini lozenge
Study: 32067098
Drug: Polyphenol-rich (PR)
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol-rich (PR) supplements (4.8 g/day for 4 months)
Study: 32067098
Drug: Polyphenols-free (PF)
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenols-free (PF) supplements (4.8 g/day for 4 months)
Study: 33901452
Drug: Double Thread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Thread Suspension (DTS)
Study: 34526071
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored diet and oral health advice
Study: 32608554
Drug: MNS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNS treatment group (N = 30)
Study: 35592818
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) group received 0.2% ropivacaine 4 mL/h
Study: 35592818
Drug: PIBI1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIBI1 group received intermittent 0.2% ropivacaine boluses at 4 mL/h
Study: 35592818
Drug: PIBI2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIBI2 group received intermittent 0.2% ropivacaine boluses at 8 mL/2 h
Study: 35592818
Drug: PIBI3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIBI3 group received intermittent 0.2% ropivacaine boluses at 12 mL/3 h
Study: 33785415
Drug: Daily smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smoking history
Study: 35645222
Drug: Additional rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional rapid-acting insulin administered at +0h
Study: 35645222
Drug: Additional rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional rapid-acting insulin administered at +1h
Study: 35645222
Drug: Additional rapid-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional rapid-acting insulin administered at +2h